Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.2K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.2K
Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

14.6K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
14.6K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

917
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
917
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

657
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
657
Infectious Diseases and Their Occurrence01:28

Infectious Diseases and Their Occurrence

31
Infectious diseases appear in populations through various transmission patterns, influenced by pathogen characteristics, population immunity, environmental conditions, and social behavior. Understanding these patterns is essential for effective public health surveillance and intervention. These categories—sporadic, outbreak, epidemic, pandemic, and endemic—help frame the nature and scope of disease events.Sporadic diseases occur irregularly and infrequently, without a predictable...
31
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

16
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-COVID: a specific neuropsychological profile in performance deficits.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Patients Suffering From Post-COVID-19 Syndrome Feature Enhanced Antibody Reactivity Towards Specific Linear Epitopes Within EBV EBNA1.

Scandinavian journal of immunology·2026
Same author

Transcriptome analysis of classical blood cells reveals downregulation of pro-inflammatory genes in the classical monocytes of long COVID patients.

Frontiers in immunology·2025
Same author

Long-term persistence and boostability of immune responses following different rabies pre-exposure prophylaxis priming schedules of a purified chick embryo cell rabies vaccine administered alone or concomitantly with a Japanese encephalitis vaccine.

PLoS neglected tropical diseases·2025
Same author

Long/Post-Covid - An Interdisciplinary Challenge.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin·2025
Same author

The type of the first prime/boost vaccine against SARS-CoV-2 exerts long-term effects on the humoral immune response.

Clinical immunology (Orlando, Fla.)·2025

Related Experiment Video

Updated: Mar 24, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Disease-modifying therapies and infectious risks in multiple sclerosis.

Alexander Winkelmann1, Micha Loebermann2, Emil C Reisinger2

  • 1Department of Neurology, University of Rostock, Gehlsheimer Strasse 20, 18147 Rostock, Germany.

Nature Reviews. Neurology
|March 5, 2016
PubMed
Summary

Multiple sclerosis (MS) treatments increase infection risk. This review details drug actions, infection risks, and strategies to manage infections in MS patients.

More Related Videos

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.7K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.3K

Related Experiment Videos

Last Updated: Mar 24, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.7K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.3K

Area of Science:

  • Neuroimmunology
  • Infectious Disease Management in Autoimmune Disorders

Background:

  • Immunomodulatory and immunosuppressive therapies for multiple sclerosis (MS) are linked to a higher incidence of infections.
  • Managing these treatment-associated infections presents a significant challenge in routine clinical practice for MS patients.
  • The growing array of available MS drugs necessitates comprehensive understanding of their infection risks and management protocols.

Purpose of the Study:

  • To review the mechanisms of action for current multiple sclerosis drugs.
  • To correlate drug mechanisms with known infection risks associated with each therapy.
  • To outline strategies for minimizing and managing treatment-related infections in MS patients.

Main Methods:

  • Literature review of immunomodulatory and immunosuppressive treatments for multiple sclerosis.
  • Analysis of drug mechanisms of action in relation to infectious complications.
  • Synthesis of current knowledge on drug-specific infection risks and risk-mitigation strategies.

Main Results:

  • Different MS therapies possess distinct mechanisms that influence susceptibility to specific infections.
  • Understanding these drug-specific risks is crucial for proactive management.
  • Individualized risk stratification is essential for selecting and monitoring MS therapies.

Conclusions:

  • An interdisciplinary approach is vital for evaluating and managing infectious events in patients undergoing MS treatment.
  • Personalized assessment of infection risk is necessary before, during, and after immunotherapy for multiple sclerosis.
  • Knowledge of drug actions and associated infectious risks informs safer and more effective MS treatment strategies.